Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;14(1):2150452.
doi: 10.1080/21505594.2022.2150452.

Pathogenicity and virulence of Clostridioides difficile

Affiliations
Review

Pathogenicity and virulence of Clostridioides difficile

Jessica E Buddle et al. Virulence. 2023 Dec.

Abstract

Clostridioides difficile is the most common cause of nosocomial antibiotic-associated diarrhea, and is responsible for a spectrum of diseases characterized by high levels of recurrence, morbidity, and mortality. Treatment is complex, since antibiotics constitute both the main treatment and the major risk factor for infection. Worryingly, resistance to multiple antibiotics is becoming increasingly widespread, leading to the classification of this pathogen as an urgent threat to global health. As a consummate opportunist, C. difficile is well equipped for promoting disease, owing to its arsenal of virulence factors: transmission of this anaerobe is highly efficient due to the formation of robust endospores, and an array of adhesins promote gut colonization. C. difficile produces multiple toxins acting upon gut epithelia, resulting in manifestations typical of diarrheal disease, and severe inflammation in a subset of patients. This review focuses on such virulence factors, as well as the importance of antimicrobial resistance and genome plasticity in enabling pathogenesis and persistence of this important pathogen.

Keywords: CDI; antimicrobial resistance; c. difficile; spores; toxins; virulence factors.

PubMed Disclaimer

Conflict of interest statement

RPF has an active collaboration with Summit Therapeutics and they are CASE partner for JEB’s PhD studentship.

Figures

Figure 1.
Figure 1.
Structure of the spore and life cycle.
Figure 2.
Figure 2.
The pathogenicity locus and toxin mode of action. .
Figure 3.
Figure 3.
Mechanisms of resistance to commonly used antibiotics. .

References

    1. Adams CM, Eckenroth BE, Putnam EE, et al. Structural and functional analysis of the CspB protease required for Clostridium spore germination. PLoS Pathog. 2013;9(2):e1003165. - PMC - PubMed
    1. ECDC , n.d. Clostridium difficile infections - facts and surveillance [WWW Document]. European Centre for Disease Prevention and Control [cited 2022 Mar 22]. Available from https://www.ecdc.europa.eu/en/Clostridium-difficile-infections/facts
    1. Liao F, Li W, Gu W, et al. A retrospective study of community-acquired Clostridium difficile infection in southwest China. Sci Rep. 2018;8(1):1–25. - PMC - PubMed
    1. Rupnik M, Wilcox MH, Gerding DN.. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nature rev Microbiol. 2009;7(7):526–536. - PubMed
    1. Cole SA, Stahl TJ. Persistent and recurrent Clostridium difficile colitis. Clin Colon Rectal Surg. 2015;28(02):65–69. - PMC - PubMed

Publication types